Publication

Article

CURE

Winter 2010
Volume9
Issue 4

Online Tool Helps Childhood Cancer Survivors Monitor Late Effects

Online tool helps cancer survivors know what to look for years after treatment

The increase of five-year survival rates of childhood cancers to 80 percent signifies a need for research and awareness of late effects of cancer and its treatment. Late effects, such as heart failure or secondary cancers, can occur years after a person finishes treatment and affect more than two-thirds of childhood cancer survivors.

The National Children’s Cancer Society offers an interactive survey, the Late Effects Assessment Tool, for pediatric cancer survivors of any age to assess their risk of various late effects.

The survey takes a few minutes to complete and provides a comprehensive list of possible late effects, although risks vary according to cancer, treatment and individual patient characteristics. Survivors are encouraged to print out the completed report and discuss the possible late effects with their medical team to determine the best strategy for follow-up and screening for specific late effects. The report also includes a directory of clinics that adhere to the Pediatric Oncology Group Resource guidelines for childhood cancer survivors.

The tool, which the NCCS developed with Robert Hayashi, MD, the director of hematology/oncology at the St. Louis Children’s Hospital, requires registration, but all information is private, and users can opt-in to save their information with the site for later use. Information is updated twice a year to include the latest research and approved treatments for various cancers.

Related Videos
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of man wearing baseball cap backwards.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
Image of doctor with brown hair.
Image of man with black hair.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Related Content